1. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia
- Author
-
Bernd Frye, H Kreipe, Hartmut Hecker, N von Neuhoff, Arnold Ganser, Guntram Buesche, Dorothea Gadzicki, Oliver Bock, and Brigitte Schlegelberger
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,medicine.drug_class ,Fusion Proteins, bcr-abl ,Pilot Projects ,Gastroenterology ,Piperazines ,Tyrosine-kinase inhibitor ,Bone Marrow ,Recurrence ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers, Tumor ,medicine ,Humans ,Protein Kinase Inhibitors ,Aged ,Salvage Therapy ,Hematology ,business.industry ,Remission Induction ,Interferon-alpha ,Myeloid leukemia ,Imatinib ,Janus Kinase 2 ,Middle Aged ,Prognosis ,medicine.disease ,Leukemia ,Pyrimidines ,medicine.anatomical_structure ,Imatinib mesylate ,Oncology ,Primary Myelofibrosis ,Benzamides ,Disease Progression ,Imatinib Mesylate ,Cancer research ,Bone marrow ,business ,Follow-Up Studies ,medicine.drug ,Chronic myelogenous leukemia - Abstract
In chronic myeloid leukemia (CML), imatinib may reverse bone marrow fibrosis (MF). Whether the unfavorable prognosis of MF is also reversed and whether imatinib guarantees against evolution of MF are unclear as yet. Fifty-nine patients with Ph+ CML treated with > or = 400 mg imatinib/day were examined for MF in 6- to 12-month intervals. Imatinib effectively reversed initial MF (P
- Published
- 2007
- Full Text
- View/download PDF